Clinical trials: Diabetic Macular Oedema
Diabetic Macular Edema
Sequentially Combined Vitrectomy, IVTA and Macular Focal Laser Photocoagulation for Diabetic Macular Edema
Macular edema constitutes the primary cause of visual impairment in diabetic patients with a disease duration of 20 years or more.
- Trial name
- NCT00371410
- Testing
- vitrectomy, intravitreal triamcinolone acetonide, macular focal laser photocoagulation
- Where
- South Korea
- Sponsor
- Samsung Medical Center
Diabetic Macular Edema, Diabetic Retinopathy
ADVM-022 Intravitreal Gene Therapy for DME
A Phase 2, Multi-Center, Randomized, Double-Masked*, Active Controlled Study of ADVM-022 (AAV.7m8-aflibercept) in Subjects with Diabetic Macular Edema [INFINITY]
- Trial name
- INFINITY (NCT04418427)
- Testing
- 6E11 vg/eye of ADVM-022, 2E11 vg/eye of ADVM-022, Aflibercept
- Where
- 14 sites in United States, Puerto Rico
- Volunteers
- 36 people
- Sponsor
- Adverum Biotechnologies, Inc.
Diabetic Macular Edema, Diabetic Retinopathy
Intravitreal Dexamethasone vs Bevacizumab in Aboriginal People With DMO
DMO is the most common cause of visual loss in people with diabetes. Regular injections of bevacizumab (Avastin) given as frequently as every month remain the current standard of care for centre-involving DMO; however, this…
- Trial name
- OASIS (NCT04619303)
- Testing
- Dexamethasone intravitreal implant, Bevacizumab Injectable Product
- Where
- 13 sites in Australia
- Volunteers
- 59 people
- Sponsor
- Lions Eye Institute, Perth, Western Australia
Diabetic Retinopathy
A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin)
This study will provide preliminary data on the dose and dose interval related effects of intravitreally administered Avastin on retinal thickness and visual acuity in subjects with Diabetic Macular Edema (DME) to aid in planning…
- Trial name
- Bevacizumab (NCT00336323)
- Testing
- Laser Photocoagulation, Bevacizumab
- Where
- 34 sites in United States
- Volunteers
- 121 people
- Sponsor
- Jaeb Center for Health Research
Diabetic Retinopathy
Triamcinolone Acetonide Injections to Treat Diabetic Macular Edema
This study will evaluate which of the three following treatment options is better for diabetic macular edema: laser alone, steroid injection alone, or steroid injection followed by laser.
- Trial name
- NCT00231023
- Testing
- Peribulbar Triamcinolone Acetonide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Eye Institute (NEI)
Diabetic Retinopathy, Macular Edema
Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab
Treatment of diabetic macular edema with intravitreal aflibercept in subjects previously treated with intravitreal anti-Vascular endothelial growth factor (VEGF) agents (ranibizumab or bevacizumab)
- Trial name
- SwapTwo (NCT02559180)
- Testing
- aflibercept
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Rishi Singh
Diabetic Macular Edema
A Safety and Efficacy Trial of a Treat and Extend Protocol Using Ranibizumab With and Without Laser Photocoagulation for Diabetic Macular Edema
The purpose of this research study is to determine if a "Treat and Extend" regimen (increasing the time between visits when the disease is stable and not getting worse) of Ranibizumab 0.3 mg injections inside the eye is safe and…
- Trial name
- TREX-DME (NCT01934556)
- Testing
- Ranibizumab 0.3 mg intravitreal injection, Guided Laser Photocoagulation
- Where
- 3 sites in United States
- Volunteers
- 150 people
- Sponsor
- Palmetto Retina Center, LLC
Cystoid Macular Edema, Postoperative, Diabetes Mellitus
Effect of Preoperative Topical Ketorolac on Aqueous Cytokine Levels and Macular Thickness in Cataract Surgery Patients
The purpose of this study is to determine whether there is a relationship between inflammatory cytokines in the aqueous of the eye and thickness of the macula after treatment of topical ketorolac for patients undergoing cataract…
- Trial name
- NCT02646072
- Testing
- Ketorolac tromethamine ophthalmic solution 0.45%
- Where
- Malaysia
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Malaya
Diabetic Macular Edema, Visual Impairment
Efficacy and Safety of Ranibizumab (Intravitreal Injections) Versus Laser Treatment in Patients With Visual Impairment Due to Diabetic Macular Edema
This study will assess the efficacy and safety of ranibizumab (intravitreal injections) versus laser treatment in patients with visual impairment due to diabetic macular edema.
- Trial name
- RED-ES (NCT00901186)
- Testing
- RFB002, Laser photocoagulation
- Where
- 17 sites in Spain
- Volunteers
- 83 people
- Sponsor
- Novartis Pharmaceuticals
Macular Edema Due to Diabetes Mellitus
Home Monitoring of Diabetic Macular Edema
Diabetic macular edema (DME) is part of diabetic retinopathy (DR) and a leading cause of central visual loss in people with diabetes .
- Trial name
- NCT05223569
- Testing
- Home OCT monitoring model, Hospital-based monitoring with a staff-administrated OCT
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Diabetic Macular Edema
Lactiplantibacillus Plantarum 299v Probiotic Supplementation in Patients With Diabetic Macular Edema
This pilot prospective, interventional, longitudinal study, aims to evaluate the potential benefits of the probiotic supplement Lactobacillus plantarum 299v in patients with diabetic macular edema (DME).
- Trial name
- NCT07383701
- Testing
- Lactobacillus plantarum 299v
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Massachusetts Eye and Ear Infirmary
Diabetic Retinopathy, Diabetic Macular Edema
Prevalence of DIAbetic RETinopathy and Impact of Genetic Factors in the Development of Diabetic Retinopathy of Patients With Type 1 and 2 Diabetes Mellitus in SlovaKia
The aim of the study is to find out prevalence and individual stages of Diabetic Retinopathy in patients with type 1 and type 2 DM verified based on complex ophthalmologic measurements in Slovak Republic.
- Conditions
- Diabetic Retinopathy, Diabetic Macular Edema, Diabetes Mellitus
- Trial name
- DIARET SK (NCT02232503)
- Testing
- Studied cohort
- Volunteers
- 4,011 people
- Sponsor
- Novartis Slovakia, s.r.o.
Diabetes Mellitus, Diabetic Retinopathy
A Study to Evaluate THR-317 and Ranibizumab Combination Treatment for Diabetic Macular Oedema (DME)
This study is conducted to evaluate the safety of intravitreal THR-317 administered in combination with ranibizumab, and to assess the efficacy of the combination treatment in improving best-corrected visual acuity (BCVA) and…
- Conditions
- Diabetes Mellitus, Diabetic Retinopathy, Macular Edema
- Trial name
- NCT03499223
- Testing
- Ranibizumab 0.5mg, THR-317 8mg
- Where
- 37 sites in Belgium, France and 5 more
- Volunteers
- 70 people
- Sponsor
- Oxurion
Diabetic Retinopathy
Routine Clinical Practice for Use of Intravitreal Aflibercept Treatment in Patients With Diabetic Macular Edema
The main objectives of this observational study were to describe outcomes, monitoring and treatment patterns of patients with diabetic macular edema in routine clinical practice who are either treatment naïve patients or…
- Trial name
- APOLLON (NCT02924311)
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- France
- Volunteers
- 402 people
- Sponsor
- Bayer
Macular Edema
Comparison of Intravitreal Ranibizumab and Macular Grid-pattern Laser for Treatment of Diabetic Macular Edema
This study investigates the hypothesis that ranibizumab injection given into the eye is an efficacious and safe treatment option applied for swelling of the macula (site of sharp vision) in diabetes.
- Trial name
- NCT00994799
- Testing
- ranibizumab, macular grid-pattern laser
- Where
- 3 sites in Hungary
- Volunteers
- 50 people
- Sponsor
- Szeged University
Diabetic Macular Edema
Suprachoroidal Triamcinolone Acetonide Monotherapy in Treatment-naive Center Involving Diabetic Macular Edema
The goal of this clinical trial is to evaluate whether a single injection of suprachoroidal triamcinolone acetonide (SCTA) improves visual outcomes in patients with treatment-naive diabetic macular edema involving the center of…
- Trial name
- SCTA CI-DME (NCT07870226)
- Testing
- Suprachoroidal triamcinolone acetonide injection
- Volunteers
- 25 people
- Sponsor
- Khyber Girls Medical College
Diabetic Macular Edema
Rapid Structural and Functional Improvements in Following 0.19 mg Fluocinolone Acetonide (FAc) Implant in Diabetic Macular Edema Patients With Poor Visual Acuity: 12-month Audit Results From United Arab Emirates
The Health Authority - Abu Dhabi (HAAD) approved the reimbursement of the slow release FAc implant (ILUVIEN) and it is now available for the treatment of diabetic macular edema (DME) in persons who have been previously treated…
- Trial name
- NCT03590587
- Testing
- 0.19 mg fluocinolone acetonide (FAc) implant
- Where
- United Arab Emirates
- Volunteers
- 30 people
- Sponsor
- Benha University
Diabetic Macular Edema
Change Oxygen Consumption Following Intravitreal Treatment of Lucentis (Ranibizumab) in Eyes With Diabetic Macular Edema
Recent reports suggest that anti-VEGF agents (ranibizumab) may suppress the progression of retinal nonperfusion area. This protective effect would cause the increase of the oxygen consumption in the diabetic retina.
- Trial name
- NCT02329132
- Testing
- Ranibizumab
- Where
- Japan
- Volunteers
- 30 people
- Sponsor
- Kagawa University
Diabetic Macular Edema
Pilot Study of OCT Versus Fluorescein Angiography in DME
Diabetic Macular Edema (DME), which can happen as a complication of diabetes, occurs when fluid and proteins collect in the macula (the yellow central area of the retina).
- Trial name
- OCT and DME (NCT01876914)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Oregon Health and Science University
Diabetic Macular Edema
Extension Study of MYL-1701P-3001 for Safety and Efficacy
This Study (AFIL-IJZ-3002) is designed to evaluate the safety, efficacy and immunogenicity of MYL-1701P among a group of participants successfully completing MYL-1701P-3001 (NCT03610646) study.
- Trial name
- NCT04674800
- Testing
- MYL-1701P, a proposed biosimilar to Eylea
- Where
- 15 sites in India
- Volunteers
- 52 people
- Sponsor
- Mylan Pharmaceuticals Inc